BR112023021587A2 - Fab anti-tslp com estabilidade melhorada, kit, composição, vetor, célula, método de produção e usos - Google Patents
Fab anti-tslp com estabilidade melhorada, kit, composição, vetor, célula, método de produção e usosInfo
- Publication number
- BR112023021587A2 BR112023021587A2 BR112023021587A BR112023021587A BR112023021587A2 BR 112023021587 A2 BR112023021587 A2 BR 112023021587A2 BR 112023021587 A BR112023021587 A BR 112023021587A BR 112023021587 A BR112023021587 A BR 112023021587A BR 112023021587 A2 BR112023021587 A2 BR 112023021587A2
- Authority
- BR
- Brazil
- Prior art keywords
- vector
- improved stability
- fab
- kit
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169183 | 2021-04-19 | ||
| PCT/EP2022/060236 WO2022223514A1 (en) | 2021-04-19 | 2022-04-19 | An anti-tslp fab with improved stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021587A2 true BR112023021587A2 (pt) | 2023-12-19 |
Family
ID=75588042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021587A BR112023021587A2 (pt) | 2021-04-19 | 2022-04-19 | Fab anti-tslp com estabilidade melhorada, kit, composição, vetor, célula, método de produção e usos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240199730A1 (enExample) |
| EP (1) | EP4326767A1 (enExample) |
| JP (1) | JP2024516962A (enExample) |
| KR (1) | KR20230172508A (enExample) |
| CN (1) | CN117222665A (enExample) |
| AR (1) | AR125379A1 (enExample) |
| AU (1) | AU2022263281A1 (enExample) |
| BR (1) | BR112023021587A2 (enExample) |
| CA (1) | CA3216894A1 (enExample) |
| CL (1) | CL2023003082A1 (enExample) |
| CO (1) | CO2023015286A2 (enExample) |
| CR (1) | CR20230533A (enExample) |
| EC (1) | ECSP23086870A (enExample) |
| IL (1) | IL307651A (enExample) |
| MX (1) | MX2023012266A (enExample) |
| PH (1) | PH12023552762A1 (enExample) |
| SA (1) | SA523451188B1 (enExample) |
| TW (1) | TW202306982A (enExample) |
| WO (1) | WO2022223514A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66646B1 (sr) * | 2019-10-28 | 2025-04-30 | Medimmune Ltd | Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| WO2025163008A1 (en) | 2024-01-29 | 2025-08-07 | Astrazeneca Ab | Compositions of thymic stromal lymphopoietin (tslp) binding fragments and methods of use thereof |
| USD1126392S1 (en) | 2024-05-16 | 2026-05-12 | Astrazeneca Ab | Inhaler |
| US20260034317A1 (en) | 2024-05-20 | 2026-02-05 | Medimmune Limited | Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2429544C (en) | 2000-11-17 | 2010-10-19 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| JP7330896B2 (ja) * | 2017-04-12 | 2023-08-22 | アムジェン インコーポレイテッド | 抗ｔｓｌｐ抗体による喘息治療 |
| JP7331298B2 (ja) * | 2019-09-04 | 2023-08-23 | ビオシオン インコーポレイテッド | 抗体結合ｔｓｌｐ及びその使用 |
| RS66646B1 (sr) * | 2019-10-28 | 2025-04-30 | Medimmune Ltd | Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe |
-
2022
- 2022-04-19 CR CR20230533A patent/CR20230533A/es unknown
- 2022-04-19 JP JP2023563876A patent/JP2024516962A/ja active Pending
- 2022-04-19 CN CN202280029099.0A patent/CN117222665A/zh active Pending
- 2022-04-19 AU AU2022263281A patent/AU2022263281A1/en active Pending
- 2022-04-19 TW TW111114769A patent/TW202306982A/zh unknown
- 2022-04-19 BR BR112023021587A patent/BR112023021587A2/pt unknown
- 2022-04-19 KR KR1020237038201A patent/KR20230172508A/ko active Pending
- 2022-04-19 WO PCT/EP2022/060236 patent/WO2022223514A1/en not_active Ceased
- 2022-04-19 US US18/287,240 patent/US20240199730A1/en active Pending
- 2022-04-19 PH PH1/2023/552762A patent/PH12023552762A1/en unknown
- 2022-04-19 CA CA3216894A patent/CA3216894A1/en active Pending
- 2022-04-19 EP EP22724429.0A patent/EP4326767A1/en active Pending
- 2022-04-19 AR ARP220101003A patent/AR125379A1/es unknown
- 2022-04-19 MX MX2023012266A patent/MX2023012266A/es unknown
- 2022-04-19 IL IL307651A patent/IL307651A/en unknown
-
2023
- 2023-10-17 CL CL2023003082A patent/CL2023003082A1/es unknown
- 2023-10-18 SA SA523451188A patent/SA523451188B1/ar unknown
- 2023-11-14 CO CONC2023/0015286A patent/CO2023015286A2/es unknown
- 2023-11-16 EC ECSENADI202386870A patent/ECSP23086870A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SA523451188B1 (ar) | 2025-06-22 |
| AU2022263281A1 (en) | 2023-11-09 |
| JP2024516962A (ja) | 2024-04-18 |
| WO2022223514A1 (en) | 2022-10-27 |
| ECSP23086870A (es) | 2023-12-29 |
| AR125379A1 (es) | 2023-07-12 |
| US20240199730A1 (en) | 2024-06-20 |
| CO2023015286A2 (es) | 2024-02-05 |
| EP4326767A1 (en) | 2024-02-28 |
| CL2023003082A1 (es) | 2024-04-19 |
| PH12023552762A1 (en) | 2024-04-15 |
| TW202306982A (zh) | 2023-02-16 |
| MX2023012266A (es) | 2023-10-24 |
| IL307651A (en) | 2023-12-01 |
| CA3216894A1 (en) | 2022-10-27 |
| AU2022263281A9 (en) | 2023-11-16 |
| CR20230533A (es) | 2024-04-05 |
| CN117222665A (zh) | 2023-12-12 |
| KR20230172508A (ko) | 2023-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23086870A (es) | Un fab anti-tslp con estabilidad mejorada | |
| BR112018075688A2 (pt) | anticorpos anti-c5 e métodos de uso | |
| BR112021025130A2 (pt) | Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos | |
| BR112019006388A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
| BR112021020608A8 (pt) | Rna recrutador de desaminase, construção, método para editar um rna alvo em uma célula hospedeira, e, construção, composição, célula, biblioteca ou kit | |
| MX2019003674A (es) | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. | |
| CR20180503A (es) | Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos | |
| AR103162A1 (es) | Anticuerpos anti-c5 y métodos para su uso | |
| JOP20240159A1 (ar) | تركيبات وطريقة لتثبيط التعبير عن بروتين lpa(apo(a)) | |
| BR112018002214A2 (pt) | ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho? | |
| BRPI0915989A2 (pt) | sinal de poliadenilação, seu vetor, seu uso e seu kit, bem como célula compreendendo o vetor e método para produzir um polipeptídeo de interesse | |
| BR112019025744A8 (pt) | Método para aperfeiçoar a eficiência de transformação de planta e método para transformar planta | |
| BR112012019404B8 (pt) | Método para a preparação de moléculas de anticorpos recombinantes | |
| BR112016015678A2 (pt) | Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso | |
| DOP2022000218A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| BR112021017464A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112014022467A2 (pt) | transformantes de rasamsonia | |
| MX2020012649A (es) | Neoantígenos especificos de tumor y métodos de uso de estos. | |
| BR112023022681A2 (pt) | Vírus oncolíticos para expressão modificada de mhc | |
| BR112021024819A2 (pt) | Acetato quinase engenheirada, composição, sequência de polinucleotídeos, vetor de expressão, célula hospedeira, e, método de produção de uma acetato quinase engenheirada | |
| BR112018070510A2 (pt) | processo de tratamento de grão | |
| BR112023024706A2 (pt) | Reguladores da transcrição e polinucleotídeos que os codificam | |
| BR112022007151A2 (pt) | Produção de bioproduto em uma célula hospedeira | |
| BR112022007492A2 (pt) | Métodos para melhorar os organismos fotossintéticos | |
| BR112017012893A2 (pt) | composição de meio e método para preparar toxina botulínica |